Summary
The efficacy of different regimens of therapy for parenchymal brain cysticercosis either with praziquantel (PZQ) or with albendazole (ALB) was compared in 114 patients. Four schemes of treatment were used: PZQ 50 mg/kg per day for 15 days, PZQ 50 mg/kg per day for 8 days, ALB 15 mg/kg per day for 30 days, and ALB 15 mg/kg per day for 8 days. Three months after therapy, it was apparent that both PZQ and ALB were effective, as shown by the disappearance of cystic lesions in computed tomographic scans. Thirty-three control patients followed for a mean of 11 months had no spontaneous remission of lesions. When comparing PZQ with ALB, the latter was found to be more effective than the former for both the full and the short course of treatment: 85% vs 60% and 85% vs 48% disappearence of lesions, respectively (P<0.001). Comparison of the full vs the short course of PZQ showed that the short course had a further 12% reduction in durg effectiveness. In contrast, the length of ALB therapy could be shortened without lessening its efficacy. Based on these results, an 8-day course of ALB is recommended as treatment for parenchymal brain cysticercosis; a 15-day course of PZQ could be subsequently used in those patients who show only partial response to ALB.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alarcón F, Pérez Y, Banda H (1988) Praziquantel and dexamethasone (letter). Neurology 38:997–999
Botero C, Castaño S (1982) Treatment of cysticercosis with praziquantel in Colombia. Am J Trop Med Hyg 31:811–821
Chavarría M, González DD (1987) Droncit en el tratamiento de la cisticercosis porcina. Esp Vet (Mex) 1:149–165
Ciferri F (1988) Delayed CSF reaction to praziquantel (letter). Lancet I:642–643
DeGhetaldi LD, Norman RM, Douville AW (1983) Cerebral cysticercosis treated biphasically with dexamenthasone and praziquantel. Ann Intern Med 99:179–181
Del Brutto OH (1988) Delayed CSF reaction to praziquantel (letter). Lancet II:341
Del Brutto OH, Sotelo J (1988) Neurocysticercosis: an update. Rev Infect Dis 10:1075–1087
Escobedo F, Penagos P, Rodríguez J, Sotelo J (1987) Albendazole therapy for neurocysticercosis. Arch Intern Med 147:738–741
Leopold GW, Ungethum W, Groll E, Diekmann HW, Nowak H, Wegner DHG (1978) Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodes: an example of a complex study covering both tolerance and pharmacokinetics. Eur J Clin Pharmacol 14:281–291
Miller B, Grinnel V, Goldberg MA, Heiner D (1983) Spontaneous disappearance of cerebral cysticercosis: three cases. Neurology 33:1377–1379
Pearson RD, Guerrant RL (1983) Praziquantel: a major advance in antihelminthic therapy. Ann Intern Med 99:195–198
Robles C, Chavarría M (1979) Presentación de un caso clínico de cisticercosis cerbral tratado médicamente con un muevo fármaco. Praziquantel. Salud Pública Méx 21:603–618
Robles C, Sedano AN, Vargas-Tentori N, Galindo-Virgen S (1987) Long-term results of praziquantel therapy in neurocysticercosis. J Neurosurg 66:359–363
Rodríguez-Carbajal J, Boleaga-Durán B, Dorfsman J (1987) The role of computed tomography (CT) in the diagnosis of neurocysticercosis. Child's Nerv Syst 3:199–202
Rosas N, Sotelo J, Nieto D (1986) ELISA in the diagnosis of neurocysticercosis. Arch Neurol 43:353–356
Rossingnol JF (1981) Albendazol: estudios clínicos realizados en Franciay Africa Occidental: informe sobre 1034 casos. Comp Invest Clín Latinoam 1 [Suppl]:117–125
Saimot AG, Cremieux AC, Hay JM, Meulemans A, Giovannangeli MD, Delaitre B, Coulaus B (1983) Albendazole as a potential treatment for human hydatidosis. Lancet II:752–756
Sotelo J (1987) Cysticercosis. In: Johnson RT (ed) Current therapy in neurologic disease, vol 2. Decker, Philadelphia, pp 114–117
Sotelo J (1987) Neurocysticercosis. In: Kennedy PGE, Johnson RT (eds) Infections of the nervous system, Butterworths, London, pp 145–155
Sotelo J, Del Brutto OH (1987) Therapy of neurocysticercosis. Child's Nerv Syst 3:208–211
Sotelo J, Del Brutto OH (1989) Neurocysticercosis. In: Román GC (ed) Tropical neurology: an overview. CRC Press, Boca Raton (in press)
Sotelo J, Excobedo F, Rodríguez-Carbajal J, Torres B, Rubio-Donnadieu F (1984) Therapy of parenchymal brain cysticercosis with praziquantel. N Engl J Med 310:1001–1007
Sotelo J, Torres B, Rubio-Donnadieu F, Escobedo F, Rodríguez-Carbajal J (1985) Praziquantel in the treatment of neurocysticercosis: long-term follow-up. Neurology 35:752–755
Sotelo J, Guerrero V, Rubio F (1985) Neurocysticarcosis: a new classification based on active and inactive forms. Arch Intern Med 145:442–445
Sotelo J, Penagos P, Escobedo F, Del Brutto OH (1988) Short course of albendazole therapy for neurocysticercosis. Arch Neurol 45:1130–1133
Sotelo J, Escobedo F, Penagos P (1988) Albendazole vs praziquantel for therapy for neurocysticercosis: a controlled trial. Arch Neurol 45:532–534
Spina-Franca A, Nobrega JPS, Livramento JA Machado LR (1982) Administration of praziquantel in neurocysticercosis. Tropenmed Parasitol 33:1–4
Vázquez ML, Jung H, Sotelo J (1987) Plasma levels of praziquantel decrease when dexamethasone is given simultaneously. Neurology 37:1562
Weniger BG, Schantz PM (1984) Praziquantel and refugee health. JAMA 251:2391–2392
Zenateno M, Del Brutto OH, Houang B, Salgado P, Kien P, Sotelo J, Caille JM (1987) Neurocysticercosis en pays d'endemie (Méxicque): interét de 1'I.R.M. Proceedings, annual meeting of the societé Francaise de Neuroradiologie. Hospital de la Salpetriere, Paris, 9 December 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sotelo, J., del Brutto, O.H., Penagos, P. et al. Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis. J Neurol 237, 69–72 (1990). https://doi.org/10.1007/BF00314663
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00314663